Does the media prefer CNTB or AUTL?

In the previous week, Autolus Therapeutics had 18 more articles in the media than Connect Biopharma. MarketBeat recorded 20 mentions for Autolus Therapeutics and 2 mentions for Connect Biopharma. Autolus Therapeutics' average media sentiment score of 0.31 beat Connect Biopharma's score of 0.00 indicating that Autolus Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Connect Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Autolus Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor CNTB or RGNX?

In the previous week, REGENXBIO had 13 more articles in the media than Connect Biopharma. MarketBeat recorded 15 mentions for REGENXBIO and 2 mentions for Connect Biopharma. REGENXBIO's average media sentiment score of 0.47 beat Connect Biopharma's score of 0.00 indicating that REGENXBIO is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Connect Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral REGENXBIO 5 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer PRME or CNTB?

In the previous week, Prime Medicine had 5 more articles in the media than Connect Biopharma. MarketBeat recorded 7 mentions for Prime Medicine and 2 mentions for Connect Biopharma. Prime Medicine's average media sentiment score of 0.26 beat Connect Biopharma's score of 0.00 indicating that Prime Medicine is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prime Medicine 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Connect Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is MPLT or CNTB more profitable?

Maplight Therapeutics' return on equity of 0.00% beat Connect Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Maplight Therapeutics N/A N/A N/A Connect Biopharma N/A -122.29% -97.07%

Does the media favor MPLT or CNTB?

In the previous week, Maplight Therapeutics had 3 more articles in the media than Connect Biopharma. MarketBeat recorded 5 mentions for Maplight Therapeutics and 2 mentions for Connect Biopharma. Maplight Therapeutics' average media sentiment score of 0.78 beat Connect Biopharma's score of 0.00 indicating that Maplight Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maplight Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Connect Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is IMMX or CNTB more profitable?

Immix Biopharma's return on equity of -73.24% beat Connect Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Immix Biopharma N/A -73.24% -59.20% Connect Biopharma N/A -122.29% -97.07%

Does the media prefer IMMX or CNTB?

In the previous week, Immix Biopharma had 9 more articles in the media than Connect Biopharma. MarketBeat recorded 11 mentions for Immix Biopharma and 2 mentions for Connect Biopharma. Immix Biopharma's average media sentiment score of 0.03 beat Connect Biopharma's score of 0.00 indicating that Immix Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immix Biopharma 2 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Connect Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Connect Biopharma (CNTB) Competitors

$2.20 +0.01 (+0.46%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$2.20 0.00 (0.00%)

As of 08/7/2026 07:59 PM Eastern

Compare

CNTB vs. AUTL, RGNX, PRME, MPLT, and IMMX

Should you buy Connect Biopharma stock or one of its competitors? MarketBeat compares Connect Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Connect Biopharma include Autolus Therapeutics (AUTL), REGENXBIO (RGNX), Prime Medicine (PRME), Maplight Therapeutics (MPLT), and Immix Biopharma (IMMX). These companies are all part of the "biotechnology" industry.

How does Connect Biopharma compare to Autolus Therapeutics?

Connect Biopharma (NASDAQ:CNTB) and Autolus Therapeutics (NASDAQ:AUTL) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, media sentiment, profitability, analyst recommendations, risk and valuation.

Connect Biopharma currently has a consensus target price of $7.29, indicating a potential upside of 231.17%. Autolus Therapeutics has a consensus target price of $8.75, indicating a potential upside of 314.69%. Given Autolus Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Autolus Therapeutics is more favorable than Connect Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Connect Biopharma	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Autolus Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89

Connect Biopharma has a net margin of 0.00% compared to Autolus Therapeutics' net margin of -311.98%. Connect Biopharma's return on equity of -122.29% beat Autolus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Connect Biopharma	N/A	-122.29%	-97.07%
Autolus Therapeutics	-311.98%	-128.59%	-46.25%

Connect Biopharma has higher earnings, but lower revenue than Autolus Therapeutics. Autolus Therapeutics is trading at a lower price-to-earnings ratio than Connect Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Connect Biopharma	$60K	2,308.53	-$55.48M	-$1.15	N/A
Autolus Therapeutics	$75.39M	7.45	-$287.53M	-$1.09	N/A

58.7% of Connect Biopharma shares are owned by institutional investors. Comparatively, 72.8% of Autolus Therapeutics shares are owned by institutional investors. 22.6% of Connect Biopharma shares are owned by company insiders. Comparatively, 25.7% of Autolus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Connect Biopharma has a beta of -0.23, indicating that its share price is 123% less volatile than the broader market. Comparatively, Autolus Therapeutics has a beta of 2.07, indicating that its share price is 107% more volatile than the broader market.

In the previous week, Autolus Therapeutics had 18 more articles in the media than Connect Biopharma. MarketBeat recorded 20 mentions for Autolus Therapeutics and 2 mentions for Connect Biopharma. Autolus Therapeutics' average media sentiment score of 0.31 beat Connect Biopharma's score of 0.00 indicating that Autolus Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Connect Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Autolus Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Autolus Therapeutics beats Connect Biopharma on 11 of the 17 factors compared between the two stocks.

How does Connect Biopharma compare to REGENXBIO?

Connect Biopharma (NASDAQ:CNTB) and REGENXBIO (NASDAQ:RGNX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and valuation.

Connect Biopharma has a net margin of 0.00% compared to REGENXBIO's net margin of -112.58%. Connect Biopharma's return on equity of -122.29% beat REGENXBIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Connect Biopharma	N/A	-122.29%	-97.07%
REGENXBIO	-112.58%	-220.07%	-46.04%

58.7% of Connect Biopharma shares are owned by institutional investors. Comparatively, 88.1% of REGENXBIO shares are owned by institutional investors. 22.6% of Connect Biopharma shares are owned by company insiders. Comparatively, 14.2% of REGENXBIO shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Connect Biopharma has higher earnings, but lower revenue than REGENXBIO. REGENXBIO is trading at a lower price-to-earnings ratio than Connect Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Connect Biopharma	$60K	2,308.53	-$55.48M	-$1.15	N/A
REGENXBIO	$170.44M	3.25	-$193.88M	-$5.60	N/A

Connect Biopharma has a beta of -0.23, meaning that its share price is 123% less volatile than the broader market. Comparatively, REGENXBIO has a beta of 0.94, meaning that its share price is 6% less volatile than the broader market.

Connect Biopharma currently has a consensus price target of $7.29, suggesting a potential upside of 231.17%. REGENXBIO has a consensus price target of $24.00, suggesting a potential upside of 123.88%. Given Connect Biopharma's stronger consensus rating and higher possible upside, analysts clearly believe Connect Biopharma is more favorable than REGENXBIO.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Connect Biopharma	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
REGENXBIO	2 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.54

In the previous week, REGENXBIO had 13 more articles in the media than Connect Biopharma. MarketBeat recorded 15 mentions for REGENXBIO and 2 mentions for Connect Biopharma. REGENXBIO's average media sentiment score of 0.47 beat Connect Biopharma's score of 0.00 indicating that REGENXBIO is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Connect Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
REGENXBIO	5 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Connect Biopharma beats REGENXBIO on 9 of the 16 factors compared between the two stocks.

How does Connect Biopharma compare to Prime Medicine?

Prime Medicine (NASDAQ:PRME) and Connect Biopharma (NASDAQ:CNTB) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, media sentiment, institutional ownership, risk, earnings, profitability, analyst recommendations and valuation.

Connect Biopharma has a net margin of 0.00% compared to Prime Medicine's net margin of -4,613.11%. Connect Biopharma's return on equity of -122.29% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prime Medicine	-4,613.11%	-156.84%	-55.13%
Connect Biopharma	N/A	-122.29%	-97.07%

Prime Medicine has a beta of 2.31, suggesting that its share price is 131% more volatile than the broader market. Comparatively, Connect Biopharma has a beta of -0.23, suggesting that its share price is 123% less volatile than the broader market.

Connect Biopharma has lower revenue, but higher earnings than Prime Medicine. Prime Medicine is trading at a lower price-to-earnings ratio than Connect Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prime Medicine	$4.63M	120.15	-$201.14M	-$1.23	N/A
Connect Biopharma	$60K	2,308.53	-$55.48M	-$1.15	N/A

Prime Medicine presently has a consensus price target of $7.53, indicating a potential upside of 144.52%. Connect Biopharma has a consensus price target of $7.29, indicating a potential upside of 231.17%. Given Connect Biopharma's higher possible upside, analysts plainly believe Connect Biopharma is more favorable than Prime Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prime Medicine	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Connect Biopharma	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

70.4% of Prime Medicine shares are owned by institutional investors. Comparatively, 58.7% of Connect Biopharma shares are owned by institutional investors. 16.0% of Prime Medicine shares are owned by insiders. Comparatively, 22.6% of Connect Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Prime Medicine had 5 more articles in the media than Connect Biopharma. MarketBeat recorded 7 mentions for Prime Medicine and 2 mentions for Connect Biopharma. Prime Medicine's average media sentiment score of 0.26 beat Connect Biopharma's score of 0.00 indicating that Prime Medicine is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prime Medicine	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Connect Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Connect Biopharma beats Prime Medicine on 9 of the 17 factors compared between the two stocks.

How does Connect Biopharma compare to Maplight Therapeutics?

Maplight Therapeutics (NASDAQ:MPLT) and Connect Biopharma (NASDAQ:CNTB) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations.

Connect Biopharma has higher revenue and earnings than Maplight Therapeutics. Connect Biopharma is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maplight Therapeutics	N/A	N/A	-$161.15M	-$40.99	N/A
Connect Biopharma	$60K	2,308.53	-$55.48M	-$1.15	N/A

58.7% of Connect Biopharma shares are owned by institutional investors. 3.8% of Maplight Therapeutics shares are owned by company insiders. Comparatively, 22.6% of Connect Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Maplight Therapeutics presently has a consensus price target of $34.42, indicating a potential upside of 182.80%. Connect Biopharma has a consensus price target of $7.29, indicating a potential upside of 231.17%. Given Connect Biopharma's higher probable upside, analysts plainly believe Connect Biopharma is more favorable than Maplight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maplight Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	4 Strong Buy rating(s)	3.00
Connect Biopharma	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Maplight Therapeutics had 3 more articles in the media than Connect Biopharma. MarketBeat recorded 5 mentions for Maplight Therapeutics and 2 mentions for Connect Biopharma. Maplight Therapeutics' average media sentiment score of 0.78 beat Connect Biopharma's score of 0.00 indicating that Maplight Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maplight Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Connect Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Maplight Therapeutics' return on equity of 0.00% beat Connect Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maplight Therapeutics	N/A	N/A	N/A
Connect Biopharma	N/A	-122.29%	-97.07%

Summary

Maplight Therapeutics beats Connect Biopharma on 8 of the 14 factors compared between the two stocks.

How does Connect Biopharma compare to Immix Biopharma?

Immix Biopharma (NASDAQ:IMMX) and Connect Biopharma (NASDAQ:CNTB) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

Immix Biopharma has higher earnings, but lower revenue than Connect Biopharma. Immix Biopharma is trading at a lower price-to-earnings ratio than Connect Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immix Biopharma	N/A	N/A	-$29.44M	-$0.92	N/A
Connect Biopharma	$60K	2,308.53	-$55.48M	-$1.15	N/A

Immix Biopharma presently has a consensus price target of $20.71, indicating a potential upside of 113.11%. Connect Biopharma has a consensus price target of $7.29, indicating a potential upside of 231.17%. Given Connect Biopharma's stronger consensus rating and higher probable upside, analysts clearly believe Connect Biopharma is more favorable than Immix Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immix Biopharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Connect Biopharma	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Immix Biopharma had 9 more articles in the media than Connect Biopharma. MarketBeat recorded 11 mentions for Immix Biopharma and 2 mentions for Connect Biopharma. Immix Biopharma's average media sentiment score of 0.03 beat Connect Biopharma's score of 0.00 indicating that Immix Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immix Biopharma	2 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Connect Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Immix Biopharma has a beta of 0.11, indicating that its stock price is 89% less volatile than the broader market. Comparatively, Connect Biopharma has a beta of -0.23, indicating that its stock price is 123% less volatile than the broader market.

Immix Biopharma's return on equity of -73.24% beat Connect Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immix Biopharma	N/A	-73.24%	-59.20%
Connect Biopharma	N/A	-122.29%	-97.07%

11.3% of Immix Biopharma shares are owned by institutional investors. Comparatively, 58.7% of Connect Biopharma shares are owned by institutional investors. 30.3% of Immix Biopharma shares are owned by insiders. Comparatively, 22.6% of Connect Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Immix Biopharma beats Connect Biopharma on 9 of the 14 factors compared between the two stocks.

Get Connect Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CNTB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CNTB vs. The Competition

Export

Metric	Connect Biopharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$137.89M	$3.62B	$6.93B	$12.87B
Dividend Yield	N/A	3.77%	2.59%	9.91%
P/E Ratio	-1.91	9.03	271.11	25.24
Price / Sales	2,308.53	1,274.65	598.27	98.58
Price / Cash	N/A	98.58	71.46	49.72
Price / Book	2.93	18.10	13.25	6.22
Net Income	-$55.48M	-$13.25M	$3.45B	$342.66M
7 Day Performance	8.91%	6.24%	4.65%	4.41%
1 Month Performance	-0.90%	-2.70%	-0.80%	-0.28%
1 Year Performance	6.28%	61.17%	76.93%	22.60%

Connect Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CNTB Connect Biopharma	3.863 of 5 stars	$2.20 +0.5%	$7.29 +231.2%	+6.3%	$137.89M	$60K	N/A	110	News Coverage Positive News Upcoming Earnings Gap Up
AUTL Autolus Therapeutics	2.4345 of 5 stars	$2.08 +3.8%	$8.75 +321.7%	-10.2%	$552.28M	$75.39M	N/A	330	News Coverage Upcoming Earnings Analyst Upgrade Analyst Revision Gap Up
RGNX REGENXBIO	4.0003 of 5 stars	$10.65 -5.6%	$24.00 +125.3%	+35.7%	$548.80M	$170.44M	N/A	370	Trending News Earnings Report Analyst Forecast Gap Down
PRME Prime Medicine	3.1826 of 5 stars	$3.02 +2.2%	$7.53 +149.8%	N/A	$544.56M	$4.03M	N/A	N/A	News Coverage Earnings Report Analyst Upgrade
MPLT Maplight Therapeutics	3.4884 of 5 stars	$12.19 -8.2%	$34.42 +182.5%	N/A	$520.82M	N/A	N/A	109	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CNTB) was last updated on 8/8/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Connect Biopharma (CNTB) Competitors

CNTB vs. AUTL, RGNX, PRME, MPLT, and IMMX

How does Connect Biopharma compare to Autolus Therapeutics?

Summary

How does Connect Biopharma compare to REGENXBIO?

Summary

How does Connect Biopharma compare to Prime Medicine?

Summary

How does Connect Biopharma compare to Maplight Therapeutics?

Summary

How does Connect Biopharma compare to Immix Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTB vs. The Competition

Connect Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Connect Biopharma (CNTB) Competitors

CNTB vs. AUTL, RGNX, PRME, MPLT, and IMMX

How does Connect Biopharma compare to Autolus Therapeutics?

Do analysts recommend CNTB or AUTL?

Is CNTB or AUTL more profitable?

Which has stronger earnings & valuation, CNTB or AUTL?

Do institutionals and insiders believe in CNTB or AUTL?

Which has more volatility and risk, CNTB or AUTL?

Does the media prefer CNTB or AUTL?

Summary

How does Connect Biopharma compare to REGENXBIO?

Is CNTB or RGNX more profitable?

Do institutionals & insiders hold more shares of CNTB or RGNX?

Which has preferable earnings & valuation, CNTB or RGNX?

Which has more volatility & risk, CNTB or RGNX?

Do analysts recommend CNTB or RGNX?

Does the media favor CNTB or RGNX?

Summary

How does Connect Biopharma compare to Prime Medicine?

Is PRME or CNTB more profitable?

Which has more volatility and risk, PRME or CNTB?

Which has preferable valuation and earnings, PRME or CNTB?

Do analysts recommend PRME or CNTB?

Do institutionals and insiders believe in PRME or CNTB?

Does the media prefer PRME or CNTB?

Summary

How does Connect Biopharma compare to Maplight Therapeutics?

Which has higher valuation & earnings, MPLT or CNTB?

Do insiders & institutionals believe in MPLT or CNTB?

Do analysts recommend MPLT or CNTB?

Does the media favor MPLT or CNTB?

Is MPLT or CNTB more profitable?

Summary

How does Connect Biopharma compare to Immix Biopharma?

Which has higher earnings & valuation, IMMX or CNTB?

Do analysts prefer IMMX or CNTB?

Does the media prefer IMMX or CNTB?

Which has more risk & volatility, IMMX or CNTB?

Is IMMX or CNTB more profitable?

Do institutionals & insiders have more ownership in IMMX or CNTB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTB vs. The Competition

Connect Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools